Journal article · 2025 · Open access

P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact

Moritz Wick, Anna Carina Meyer, Oliver Damm, Annika Wülfing, Oliver Martyn, Rolf Kramer, Markus Knuf

Open Forum Infectious Diseases, 12(Supplement_1) · Published 29 January 2025 · DOI 10.1093/ofid/ofae631.828

Open PDFView at the publisherCite this paper

In brief

“P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact” is a 2025 journal article by Moritz Wick and 6 co-authors, published in Open Forum Infectious Diseases. OpenAlex counts 2 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Open Forum Infectious Diseases.

Citations
2
Most cited in
2025 (1)
Authors
7

Abstract

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections and hospitalizations among infants worldwide. In 2023, the universal RSV immunization of all infants with the novel monoclonal antibody nirsevimab was introduced in several countries. This systematic review aims to summarize early real-world evidence on achieved immunization rates as well as on the impact and effectiveness of nirsevimab prophylaxis among infants. Methods A systematic literature search for full-text publications was conducted in the databases PubMed and Embase. The review included observational studies that investigated the impact or effectiveness of nirsevimab in routine use. Clinical research, decision analytic modeling studies, and studies describing the disease burden of RSV without direct reference to nirsevimab use were excluded. Results Five studies fulfilled the inclusion criteria, including one from the United States (US), one from Luxembourg, and three studies from different regions in Spain. Population-wide immunization rates were reported in Luxembourg and several Spanish regions, all exceeding 80%. Four studies estimated the effectiveness of nirsevimab in preventing RSV-related hospitalizations, including two population-based cohort studies and two case-control studies. The effectiveness of nirsevimab in preventing RSV-related hospitalizations was calculated at 88.7% (95%-CI: 70-96), 84.4% (95%-CI: 77-90), and 82.0% (95%-CI: 66-90) in the Spanish studies and 90% (95 %-CI 75-96) in the US. While no effectiveness estimate was reported in Luxembourg, the number of RSV-related hospitalizations among infants under 6 months decreased by 69% after nirsevimab introduction compared to the same period of the previous year. Conclusion High uptake was observed in both Luxembourg and Spain. Despite methodological differences between studies and varying implementation strategies between countries, observed effects of recommending nirsevimab to all infants were largely consistent. International evidence suggests that nirsevimab substantially reduces RSV-related hospitalizations and thus relieves the burden on healthcare systems during the RSV season. Disclosures Moritz Wick, MSc, Sanofi: Employee|Sanofi: Stocks/Bonds (Public Company) Anna C. Meyer, PhD, Sanofi: Employee Oliver Damm, PhD, Sanofi: Employee Annika Wülfing, PhD, Sanofi: Employee and may hold stocks Oliver Martyn, MPH, Sanofi: Employee of Sanofi|Sanofi: Stocks/Bonds (Public Company) Rolf Kramer, PhD, Sanofi: Employee of Sanofi|Sanofi: Stocks/Bonds (Public Company)

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wick, M., Meyer, A. C., Damm, O., Wülfing, A., Martyn, O., Kramer, R., & Knuf, M. (2025). P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact. Open Forum Infectious Diseases, 12(Supplement_1). https://doi.org/10.1093/ofid/ofae631.828

MLA 9

Wick, Moritz, et al. “P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact.” Open Forum Infectious Diseases, vol. 12, no. Supplement_1, 2025. https://doi.org/10.1093/ofid/ofae631.828.

Chicago

Wick, Moritz, Anna Carina Meyer, Oliver Damm, Annika Wülfing, Oliver Martyn, Rolf Kramer, and Markus Knuf. 2025. “P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact.” Open Forum Infectious Diseases 12 (Supplement_1). https://doi.org/10.1093/ofid/ofae631.828.

Harvard

Wick, M. et al. (2025) ‘P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact’, Open Forum Infectious Diseases, 12(Supplement_1). doi:10.1093/ofid/ofae631.828.

IEEE

M. Wick et al., “P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact,” Open Forum Infectious Diseases, vol. 12, no. Supplement_1, 2025, doi: 10.1093/ofid/ofae631.828.

BibTeX

@article{wick2025prophylaxis,
  title     = {{P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact}},
  author    = {Wick, Moritz and Meyer, Anna Carina and Damm, Oliver and Wülfing, Annika and Martyn, Oliver and Kramer, Rolf and Knuf, Markus},
  journal   = {Open Forum Infectious Diseases},
  year      = {2025},
  volume    = {12},
  number    = {Supplement_1},
  doi       = {10.1093/ofid/ofae631.828},
  url       = {https://doi.org/10.1093/ofid/ofae631.828}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • respiratory syncytial virus
  • nirsevimab
  • RSV prophylaxis
  • infants
  • monoclonal antibodies
  • vaccination coverage
  • RSV-related hospitalization
  • real-world effectiveness

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wick, M., Meyer, A. C., Damm, O., Wülfing, A., Martyn, O., Kramer, R., & Knuf, M. (2025). P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact. Open Forum Infectious Diseases, 12(Supplement_1). https://doi.org/10.1093/ofid/ofae631.828

How many times has this paper been cited?

2 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Open Forum Infectious Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Moritz Wick, Anna Carina Meyer, Oliver Damm, Annika Wülfing, Oliver Martyn, Rolf Kramer, Markus Knuf.

What is the DOI of this paper?

10.1093/ofid/ofae631.828, permanently at https://doi.org/10.1093/ofid/ofae631.828. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.